As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.

All

    TOGGLE ALL / NONE

Padlock Therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

MorphoSys

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Horizon Pharma

Specialty pharma focused on
chronic inflammatory diseases –
IPO July 2011 (NASDAQ: HZNP)

Adnexus Therapeutics

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Quartet Medicine

Biomarker-guided therapies
for chronic pain
and inflammation

Crucell

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Magenta Therapeutics

Transforming stem cell
transplant therapy for auto-
immune and blood-based diseases

miRagen Therapeutics

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Replimune

Next-generation oncolytic
immunotherapies for
cancer treatment

Lysosomal Therapeutics, Inc.

Discovering new medicines
for severe
neurodegenerative diseases

Annovation Biopharma

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

deCODE genetics

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

ArQule

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Actelion

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Micromet

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Alnylam Pharmaceuticals

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Zafgen

First-in-class therapies for severe
obesity and rare genetic conditions –
IPO June 2014 (NASDAQ: ZFGN)

Harbour Antibodies

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

U3 Pharma

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Unum Therapeutics

Universal
cell-based
cancer immunotherapy

Delinia

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novexel

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Navitor Pharmaceuticals

Novel therapeutics
targeting
diseases of aging

Stromedix

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Avila Therapeutics

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Numerate

Small molecule
drug design
using statistical modeling

Kyn Therapeutics

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Egalet Corporation

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Infacare

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Synlogic

Next generation
synthetic biology platform
for novel therapeutics

Disarm Therapeutics

Preventing axonal degeneration
in patients with
neurological diseases

JenaValve

Minimally invasive
heart valve
devices

Bicycle Therapeutics

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Obsidian Therapeutics

New class of
regulated cell and
gene therapies

Intellia Therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Nimbus Therapeutics

Breakthrough computer-aided
drug design
for transformative medicines

Translate Bio

First-in-class
RNA therapies
for severe genetic diseases

F-Star Alpha Limited

Bispecific antibodies
to improve the treatment
of serious diseases

Arrow Therapeutics

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Exelixis

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

CoStim Pharmaceuticals

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Momenta Pharmaceuticals

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Surface Oncology

Cancer immunotherapies
at the interface of
innate & adaptive immunity

Ataxion

Therapies for rare,
debilitating, and underserved
neurological diseases

Arteaus Therapeutics

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Spero Therapeutics

Novel therapies
for severe, highly drug-resistant
bacterial infections

AVROBIO

Cell and gene therapies
for rare diseases
and cancer

Vitae Pharmaceuticals

Novel therapeutics using proprietary
computational chemistry –
IPO Sept 2014 (NASDAQ: VTAE)

Rodin Therapeutics

Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

IFM Therapeutics

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Luc Therapeutics

Novel therapeutics for
schizophrenia and other
severe psychiatric diseases